All In Biotech

Drug Trial Radar · NCT01376167

Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.

Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 851 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

851

Actual

Start

Apr 24, 2014

Primary completion

Nov 18, 2016

Study completion Nov 18, 2016

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Medicines for Malaria Venture
First posted
Jun 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an efficacious and well tolerated dose that can be co-administered with Chloroquine. Part 2 will investigate the safety and efficacy of the selected dose (300 mg tafenoquine) in the treatment and radical cure of Plasmodium Vivax Malaria.

Conditions

  • Malaria, Vivax

Interventions

  • Chloroquine 600mgDrug

    600mg Chloroquine given to each subject on Day 1 and Day2 of the trial

  • Chloroquine 300mgDrug

    300mg Chloroquine given to each subject on Day 3 of the trial

  • Tafenoquine 50mgDrug

    single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2

  • Tafenoquine 100mgDrug

    single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2

  • Tafenoquine 300mgDrug

    single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2

  • Tafenoquine 600mgDrug

    single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2

  • Primaquine 15mgDrug

    15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.

  • Chloroquine 600mg (Part 2 )Drug

    600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.

  • Chloroquine 300mg (Part 2 )Drug

    300mg Chloroquine given to each subject on Day 3 of the trial.

  • Tafenoquine 300mg (Part 2)Drug

    single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.

  • Primaquine 15mg (Part2 )Drug

    15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Recurrence-free Efficacy at 6 Months Post DoseTime frame: 6 months post dose

Locations

14 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bāndarban, Bangladesh

  • GSK Investigational Site

    Manaus, Amazonas, Brazil

  • GSK Investigational Site

    Porto Velho, Rondônia, Brazil

  • GSK Investigational Site

    Oddar Meancheay Province, Cambodia

  • GSK Investigational Site

    Gonder, Ethiopia

  • GSK Investigational Site

    Jimma, Ethiopia

  • GSK Investigational Site

    Bikaner, India

  • GSK Investigational Site

    Chennai, India

  • GSK Investigational Site

    Lucknow, India

  • GSK Investigational Site

    Secunderabad, India

  • GSK Investigational Site

    Iquitos, Loreto, Peru

  • GSK Investigational Site

    Rio Tuba, Bataraza, Philippines

  • GSK Investigational Site

    Bangkok, Thailand

  • GSK Investigational Site

    Tak, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.